NSN Investment Seba Biotech Selected for Ministry of Trade, Industry and Energy Supported Government Project... "Expanding the Dermacosmetic Market"

[Asia Economy Reporter Jang Hyowon] Seba Biotech (CEO Im Hyewon), an investment company of NSN, a KOSDAQ-listed company, announced on the 7th that it has been finally selected for the dermocosmetic product development project to regulate age-related skin function decline based on bio-derived materials supported by the Ministry of Trade, Industry and Energy.

The core of this government project is to develop dermocosmetic products by securing bio-derived material analysis technology to control age-related skin function decline and discovering domestic native biological materials to regulate bio-derived substances. In line with the super-aged society, the need to expand skin function regulation products using dermocosmetics is emerging. Additionally, with the recent removal of outdoor mask mandates and expectations for the transition to endemic, demand for skin beauty is expanding, increasing consumer interest.

The skin microbiome, called the "first genome" or "second genome," is a word combining microbe and biome. It refers to various microorganisms such as bacteria and viruses living in the human body, and it is known that adults have about 38 trillion of them. These microorganisms change diversely throughout a person's life and affect human diseases and health.

Last year, Seba Biotech developed microbiome-based cosmetic materials using proprietary technology and launched the world's first skin microbiome technology-based cosmetics, gaining recognition for its technological capabilities. It was also selected as the first domestic company approved for natural organic cosmetic raw materials by the Korea Conformity Laboratories (KCL).

Based on this technological capability, Seba Biotech analyzes and verifies the principles of beneficial and harmful bacteria generation and their correlation with diseases, accelerating new drug development based on skin microbiomes optimized for a healthy skin environment. It is also speeding up the development of technologies to treat skin diseases such as atopic dermatitis, acne, and psoriasis using various microorganisms obtained from the skin.

Market research firm Frost & Sullivan forecasted that the global microbiome market will grow at an average annual rate of 7.6% from 2019 and reach $108.6 billion (approximately 130 trillion KRW) by 2023.

Based on its extensive experience in analyzing and isolating numerous microbiome strains, Seba Biotech has secured intellectual property rights (IP) targeting various pathogenic bacteria, and through this, it is expected to create a new paradigm in the rapidly growing dermocosmetic market.

Im Hyewon, CEO of Seba Biotech, said, "Considering the trend that cosmetics are specializing into dermocosmetics for skin health beyond simple beauty, Seba Biotech will focus on new product development and sales," adding, "We are growing together by striving for mutual cooperation such as joint research and development through close communication with peer companies."

This content was produced with the assistance of AI translation services.